Annam is an early stage specialty biotech company focused on developing oncology products. Our goal is to provide safer, more effective, and more convenient solutions for patients using cancer-targeted medicines. We develop proprietary cancer-targeted enhancements to FDA-approved drugs to generate new therapeutic entities. This strategy expedites time for development and approval. Annam plans to expand its pipeline of oncology drug candidates using these patent-pending specialty cancer-targeted enhancements with ultra potent anticancer drugs. We further seek to extend the patent life of our products through new intellectual property protection.
